Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates ... Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3. ...

Analysts had expected profit of $4.52 billion ... the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report. Eli Lilly shares were up roughly ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

The pharmaceutical giant also issued fiscal 2025 profit guidance ... said demand for its weight loss and diabetes drugs would not meet its lofty expectations. Notably, Eli Lilly said it plans ...